TYRA
Business Services · California, United States · 49 Employees
View Company Info for Free
About
Headquarters
2656 State St, Carlsbad, California, 92008, Uni...Phone Number
(619) 728-4760Website
tyra.bioRevenue
$95.5 MillionStock Symbol
TYRAIndustry
Most Recent Scoops
Highlights
$528.8M
Total Funding Amount
$200M
Most Recent Funding Amount
4
Number of Funding Rounds
Who is TYRA
TYRA Org Chart
Is TYRA your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Click to see if TYRA had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if TYRA is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at TYRA
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on TYRA recently announced quarterly report
TYRA, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once TYRA has new funding data
Product Launch: Get notified when TYRA launches new products
Check if TYRA has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined TYRA as Masked Content
Find 2 more new buyers
Compare Similar Companies to TYRA
Compare insights from companies similar to TYRA, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
TYRA financials insights
Gather financial insights about TYRA, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
TYRA Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
TYRA Tech Stack
A closer look at the technologies used by TYRA
Most Recent Scoops
TYRA News & Media
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - -...Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares
Investors who take an interest in Tyra Biosciences, Inc. ( NASDAQ:TYRA ) should definitely note that the Chief...Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
– TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies – – First child with achondroplasia expected to be dosed in Q1 2025 – CARLSBAD, Calif., Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology...Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
- Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety...
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding TYRA
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNP, enables the rapid and precise refinement of structural drug design through iterative molecular SNPshots th... Read More